---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-25-000037"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:33:30.311071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody

## Summary
- CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.
- Second TCE bispecific to enter clinic in 2025 following CTIM-76 (Claudin 6 x CD3) earlier this year.
- Phase 1 open-label dose escalation and expansion study for advanced solid tumors (ovarian, pancreatic, lung, mesothelioma).
- Initial data for CT-95 Phase 1 trial expected in mid-2026.
- CEO Martin Lehr highlights expansion of clinical pipeline and leadership in TCE therapies.

## SEC filing metadata
- accession: 0001842952-25-000037
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/0001842952-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/cntx-20250409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-25-000037
- JSON: https://secwatch.observer/filing/0001842952-25-000037.json
- Plain text: https://secwatch.observer/filing/0001842952-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.